Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal.
The unknowns persisting in the understanding of the mode of action of anti-core lipopolysaccharide antibodies are discussed, and a study of two anti-lipid A monoclonal antibodies is reviewed. This article also critically analyzes the results of the recent clinical trials with monoclonal antibodies.
Baumgartner
J D
JD
Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004195:Disease Models, Animal; D000939:Epitopes / Q000276:immunology; D004926:Escherichia coli / Q000276:immunology; D016905:Gram-Negative Bacterial Infections / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007167:Immunotherapy; D008050:Lipid A / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology*
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000939:Epitopes; D016756:Immunoglobulins, Intravenous; D008050:Lipid A; D008070:Lipopolysaccharides